SCHEMBL2496477

SCHEMBL2496477

CC(C)(C)OC(=O)N1C[CH][CH]C1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
NR1H2 P55055 1/20 0.44
HPGD P15428 1/20 0.43
EPHX2 P34913 1/20 0.42
GPR119 Q8TDV5 1/20 0.41
PREP P48147 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ESR2 Q92731 1/20 0.41
RECQL P46063 1/20 0.41
EPHX1 P07099 1/20 0.41
MAPT P10636 2/20 0.41
KDM4E B2RXH2 1/20 0.41
THRB P10828 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL222920 0.86 PREP (0.53) USP2SMN1; SMN2NR1H2HPGDGPR119
SCHEMBL1242684 0.86 USP2 (0.52) USP2SMN1; SMN2NR1H2HPGDGPR119
SCHEMBL2951897 0.86 USP2 (0.49) USP2SMN1; SMN2HPGDEPHX2GPR119
SCHEMBL27001783 0.79 USP2 (0.46) USP2SMN1; SMN2NR1H2HPGDGPR119
SCHEMBL698803 0.78 USP2 (0.69) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL18294 0.78 USP2 (0.69) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL294179 0.75 USP2 (0.50) USP2SMN1; SMN2NR1H2HPGDGPR119
SCHEMBL16611844 0.74 USP2 (0.59) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL7858182 0.74 HPGD (0.68) USP2SMN1; SMN2HPGDEPHX2GPR119
SCHEMBL5053 0.74 HPGD (0.68) USP2SMN1; SMN2HPGDEPHX2GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030501-B2 Process for producing optically active 3-amino nitrogen-containing compounds KANEKA CORPORATION (JP) 2011-10-04 US disclosed
US-20090326246-A1 Method for Production of Optically Active 3-Amino-Nitrogenated Compound KANEKA CORPORATION (JP) 2009-12-31 US disclosed
EP-2050735-A1 METHOD FOR PRODUCTION OF OPTICALLY ACTIVE 3-AMINO-NITROGENATED COMPOUND Kaneka Corporation (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326246-A1 Method for Production of Optically Active 3-Amino-Nitrogenated Compound PNMT, NPEPPS, GNMT USP2 4010/4885SMN1; SMN2 992/4885NR1H2 4358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.